Roche in Talks to Buy Stomach Drug from Roivant for $7B: Report

Ulcerative colitis and Crohn’s disease are big business, and Roche could be all in, according to a report that has the Swiss pharma in talks to acquire a late-stage candidate from Roivant Sciences for upwards of $7 billion.